Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Anti-GD2｜NCAM1 CAR-T (Shenzhen Geno-Immune Medical ) in Glioblastoma: NCT05437328 Clinical Landscape Report 2026
16 October 2026
NCT05437328 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ALS-205 in Neurodegenerative Diseases: ACTRN12622000927729 Clinical Landscape Report 2026
16 October 2026
ACTRN12622000927729 clinical landscape for Neurodegenerative Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Temozolomide in Glioblastoma: NCT05439278 Clinical Landscape Report 2026
16 October 2026
NCT05439278 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PXL-770 in Metabolic Dysfunction Associated Steatohepatitis: NCT05441904 Clinical Landscape Report 2026
16 October 2026
NCT05441904 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
VGB-R04 in Hemophilia B: NCT05441553 Clinical Landscape Report 2026
16 October 2026
NCT05441553 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Reldesemtiv in Amyotrophic Lateral Sclerosis: NCT05442775 Clinical Landscape Report 2026
16 October 2026
NCT05442775 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Asunercept in Glioblastoma Multiforme: NCT05447195 Clinical Landscape Report 2026
16 October 2026
NCT05447195 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Epoetin Alfa in Anemia, Sickle Cell: NCT05451940 Clinical Landscape Report 2026
16 October 2026
NCT05451940 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GRO beta in Anemia, Sickle Cell: NCT05445128 Clinical Landscape Report 2026
16 October 2026
NCT05445128 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iodofalan (131I) in Glioblastoma Multiforme: NCT05450744 Clinical Landscape Report 2026
16 October 2026
NCT05450744 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bevacizumab biosimilar (Chia-tai Tianqing) in Rectal Cancer: NCT05476341 Clinical Landscape Report 2026
16 October 2026
NCT05476341 clinical landscape for Rectal Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Recurrent Glioblastoma: NCT05463848 Clinical Landscape Report 2026
16 October 2026
NCT05463848 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.